WEKO3
インデックスリンク
アイテム
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia
http://hdl.handle.net/2297/9918
http://hdl.handle.net/2297/99186f955dc9-0490-48f2-b6fd-5499ef259a70
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-03 | |||||
タイトル | ||||||
タイトル | Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Mabuchi, Hiroshi
× Mabuchi, Hiroshi× Haba, Toshihiro× Tatami, Ryozo× Miyamoto, Susumu× Sakai, Yasuyuki× Wakasugi, Takanobu× Watanabe, Akira× Koizumi, Junji× Takeda, Ryoyu |
|||||
書誌情報 |
New England Journal of Medicine 巻 305, 号 9, p. 478-482, 発行日 1981-01-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0028-4793 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00755156 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1056/nejm198108273050902 | |||||
出版者 | ||||||
出版者 | Massachusetts Medical Society | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (KMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10 in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 ± 9 to 303 ± 8 mg per deciliter (10.1 ± 0.2 to 7.88 ± 0.2 mmol per liter, mean ± S.E.M.; P<0.001), and serum triglyceride decreased from 137 ± 18 to 87 ± 9 mg per deciliter (1.55 ± 0.20 to 0.98 ± 0.1 mmol per liter; P<0.05). Intermediate-density-lipoprotein (IDL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (P<0.01, P<0.02, P<0.001, and P<0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 ± 0.07 to 0.20 ± 0.01 μg per milliliter (P<0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |